BurnsAdler Partners with X-GEN Pharmaceuticals to
Return Colistimethate for Injection to the Mexican Market
Charlotte, North Carolina (March 5, 2007) – BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”) announced today that it has entered into a long-term licensing and supply agreement with X-GEN Pharmaceuticals, Inc. (“X-GEN”) for the company’s Colistimethate for Injection USP product. BurnsAdler intends to market Colistimethate for Injection USP in Mexico, particularly to fulfill an unmet therapeutic need. Colistimethate for Injection USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, such as Escherichia Coli (E. Coli), Pseudomonas aeruginosa and Klebsiella Pnumoniae.
Carolina Cortez, Executive Vice President of BurnsAdler remarked, “We are very pleased to enter into this long-term partnership with X-GEN and to have this opportunity to restore Colistimethate for Injection USP as a safe and effective treatment option for healthcare professionals in Mexico. The very serious nature of P. aeruginosa and other gram-negative bacilli infections makes the lack of an effective patient therapy a critical focus. By working with X-GEN to address this need, Mexican physicians will once again have a viable and proven treatment alternative for their seriously ill patients.”
Susan Badia, President and Chief Executive Officer remarked, “X-Gen looks forward to this opportunity to fulfill Mexico’s physicians’ and patients’ therapeutic needs. We are pleased to have a partner in BurnsAdler as we work to serve the global healthcare community as a preferred source for generic choices, including Colistimethate for Injection USP”
About BurnsAdler Pharmaceuticals, Inc.
BurnsAdler Pharmaceuticals, Inc. is a specialty pharmaceutical company that promotes, sells and distributes products in South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler’s portfolio strategy focuses on pharmaceutical products and medical devices used in oncology, gastroenterology, cardiovascular medicine, orthopedic medicine, hospitals and other critical care settings.
About X-GEN Pharmaceuticals, Inc.
X-GEN Pharmaceuticals, Inc. is a generic drug company specializing in the manufacturing and distribution of anti-infective pharmaceutical products which serve as safe, effective and economical treatment options in patient care. By continually adding to their anti-infective product portfolio, X-GEN remains true its long standing tradition and commitment to provide affordable drug therapy choices to the healthcare community. X-GEN’s product offerings include a broad range of dosage forms, including injectables, oral solutions, oral solids, powders for prescription compounding and inhalants.
For additional information about this news release contact Carolina Cortez at +1.704.552.8410 Ext. 231. For additional information about BurnsAdler, please refer to the company’s website at www.burnsadler.com.